Series of SMZL patients treated with rituximab-based approach
| . | . | . | . | . | . | Response . | . | |
|---|---|---|---|---|---|---|---|---|
| Reference . | Year . | Study type . | Scheme . | Patient status . | N . | ORR . | Duration . | OS . |
| Rituximab monotherapy | ||||||||
| Bennett et al82,102 | 2005 | Retrospective | R monotherapy | RR | 11 | 91% | PFS 60% at 5 y | 70% at 5 y |
| Tsimberidou et al70 | 2006 | Retrospective | R monotherapy | First line | 25 | 88% | FFS 86% at 3 y | 95% at 3 y |
| Kalpadakis et al83,96 | 2007 | Retrospective | R monotherapy | First line | 16 | 100% | PFS 92% at 2.4 y | 100% at 2.1 y |
| Else et al103 | 2012 | Retrospective | R monotherapy | First line and RR | 10 | 100% | DFS 89% at 3 y | NR |
| Kalpadakis et al73 | 2013 | Retrospective | R monotherapy | First line | 58 | 95% | PFS 73% at 5 y | 92% at 5 y |
| Rituximab + chemotherapy | ||||||||
| Tsimberidou et al70 | 2006 | Retrospective | R-chemo | First line | 6 | 83% | FFS 100% at 3 y | 100% at 3 y |
| Cervetti et al85,86 | 2010 | Retrospective | R-2CDA | First line and RR | 47* | 87% | PFS 80% at 5 y | 86% at 5 y |
| Else et al103 | 2012 | Retrospective | R-chemo | First line and RR | 33 | 100% | DFS 71% at 3 y | NR |
| Iannitto et al87 | 2015 | Prospective | R-COMP | First line | 51 | 84% | PFS 54% at 6 y | 72% at 6 y |
| . | . | . | . | . | . | Response . | . | |
|---|---|---|---|---|---|---|---|---|
| Reference . | Year . | Study type . | Scheme . | Patient status . | N . | ORR . | Duration . | OS . |
| Rituximab monotherapy | ||||||||
| Bennett et al82,102 | 2005 | Retrospective | R monotherapy | RR | 11 | 91% | PFS 60% at 5 y | 70% at 5 y |
| Tsimberidou et al70 | 2006 | Retrospective | R monotherapy | First line | 25 | 88% | FFS 86% at 3 y | 95% at 3 y |
| Kalpadakis et al83,96 | 2007 | Retrospective | R monotherapy | First line | 16 | 100% | PFS 92% at 2.4 y | 100% at 2.1 y |
| Else et al103 | 2012 | Retrospective | R monotherapy | First line and RR | 10 | 100% | DFS 89% at 3 y | NR |
| Kalpadakis et al73 | 2013 | Retrospective | R monotherapy | First line | 58 | 95% | PFS 73% at 5 y | 92% at 5 y |
| Rituximab + chemotherapy | ||||||||
| Tsimberidou et al70 | 2006 | Retrospective | R-chemo | First line | 6 | 83% | FFS 100% at 3 y | 100% at 3 y |
| Cervetti et al85,86 | 2010 | Retrospective | R-2CDA | First line and RR | 47* | 87% | PFS 80% at 5 y | 86% at 5 y |
| Else et al103 | 2012 | Retrospective | R-chemo | First line and RR | 33 | 100% | DFS 71% at 3 y | NR |
| Iannitto et al87 | 2015 | Prospective | R-COMP | First line | 51 | 84% | PFS 54% at 6 y | 72% at 6 y |
2CDA, 2-chlorodeoxyadenosine; chemo, chemotherapy; DFS, disease-free survival; R, rituximab; RR, relapsed/refractory.
Rituximab in 32 patients.